AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] Ligand Pharmaceuticals Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Andrew Reardon, Chief Legal Officer and Secretary of Ligand Pharmaceuticals (LGND), reported that 1,325 shares of common stock were withheld by the issuer to satisfy the tax liability arising from the settlement of restricted stock units. The withholding used a price of $150.06 per share.

After the withholding, Reardon beneficially owns 30,811 shares, reported as direct ownership. The filing lists transaction code F and the form's explanation explicitly states the withheld shares paid the tax liability on RSU settlement. This disclosure reflects a routine, compensation-related withholding rather than an open-market sale or purchase.

Andrew Reardon, Chief Legal Officer e Segretario di Ligand Pharmaceuticals (LGND), ha comunicato che 1,325 azioni ordinarie sono state trattenute dall'emittente per soddisfare l'obbligo fiscale derivante dal regolamento delle unità azionarie vincolate (RSU). La ritenuta è stata effettuata usando un prezzo di $150.06 per azione.

Dopo la ritenuta, Reardon possiede beneficiariamente 30,811 azioni, riportate come proprietà diretta. Il deposito riporta il codice transazione F e la spiegazione del modulo dichiara esplicitamente che le azioni trattenute hanno pagato l'obbligo fiscale relativo al regolamento delle RSU. Questa comunicazione riflette una trattenuta di routine legata alla retribuzione e non una vendita o un acquisto sul mercato aperto.

Andrew Reardon, director legal y secretario de Ligand Pharmaceuticals (LGND), informó que el emisor retuvo 1,325 acciones ordinarias para satisfacer la obligación fiscal derivada del liquidación de unidades de acciones restringidas (RSU). La retención se realizó utilizando un precio de $150.06 por acción.

Tras la retención, Reardon posee beneficiariamente 30,811 acciones, reportadas como propiedad directa. La presentación indica el código de transacción F y la explicación del formulario declara explícitamente que las acciones retenidas pagaron la obligación fiscal de la liquidación de las RSU. Esta divulgación refleja una retención rutinaria relacionada con la compensación y no una venta o compra en el mercado abierto.

Andrew Reardonì€ Ligand Pharmaceuticals(LGND)ì� 최고법무책임ìž� ê²� 서기ì´ë©°, 발행ì¸ì´ 제한주ì‹ë‹¨ìœ„(RSU) ê²°ì œë¡� ë°œìƒí•� 세금 ë‚©ë¶€ë¥� 위해 1,325ì£� 보통ì£�ë¥� ì›ì²œì§•수했다ê³� 보고했습니다. ì›ì²œì§•수ëŠ� 주당 $150.06ì� ê°€ê²©ì„ ì‚¬ìš©í•˜ì—¬ ì´ë£¨ì–´ì¡ŒìŠµë‹ˆë‹�.

ì›ì²œì§•수 í›� ReardonëŠ� ì§ì ‘ 소유ë¡� ë³´ê³ ë� 30,811ì£�ë¥� 사실ìƒ� 보유하고 있습니다. 신고서ì—ëŠ� 거래 코드 Fê°€ 기재ë˜ì–´ 있으ë©�, ì–‘ì‹ì� ì„¤ëª…ì€ ì›ì²œì§•수ë� 주ì‹ì� RSU ê²°ì œì—� 대í•� 세금 ì˜ë¬´ë¥� 납부했다ê³� 명확íž� ë°ížˆê³� 있습니다. ì� 공시ëŠ� 공개 시장ì—서ì� 매매가 아니ë� ë³´ìƒ ê´€ë ¨ì˜ ì¼ìƒì ì¸ ì›ì²œì§•수ë¥� ë°˜ì˜í•©ë‹ˆë‹�.

Andrew Reardon, directeur juridique et secrétaire de Ligand Pharmaceuticals (LGND), a déclaré que l'émetteur avait retenu 1,325 actions ordinaires pour satisfaire l'obligation fiscale résultant du règlement d'unités d'actions restreintes (RSU). La retenue a été effectuée en utilisant un prix de $150.06 par action.

Après la retenue, Reardon détient bénéficiairement 30,811 actions, déclarées comme propriété directe. Le dépôt indique le code de transaction F et l'explication du formulaire précise explicitement que les actions retenues ont réglé l'obligation fiscale liée au règlement des RSU. Cette divulgation reflète une retenue courante liée à la rémunération et non une vente ou un achat sur le marché ouvert.

Andrew Reardon, Chief Legal Officer und Sekretär von Ligand Pharmaceuticals (LGND), meldete, dass vom Emittenten 1,325 Stammaktien einbehalten wurden, um die Steuerverpflichtung aus der Abwicklung von Restricted Stock Units (RSU) zu erfüllen. Die Einbehaltung erfolgte zu einem Preis von $150.06 je Aktie.

Nach der Einbehaltung besitzt Reardon wirtschaftlich 30,811 Aktien, angegeben als Direktbesitz. Die Meldung nennt den Transaktionscode F und die Erläuterung des Formulars führt ausdrücklich an, dass die einbehaltenen Aktien die Steuerverpflichtung bei der RSU-Abrechnung beglichen haben. Diese Offenlegung stellt eine routinemäßige, vergütungsbezogene Einbehaltung dar und keinen Kauf oder Verkauf am offenen Markt.

Positive
  • None.
Negative
  • None.

Insights

TL;DR Routine RSU tax withholding: 1,325 shares withheld at $150.06, leaving 30,811 shares beneficially owned.

The reported transaction is a compensation-related withholding rather than an active sale or purchase, so it has limited immediate impact on LGND's capital structure or market dynamics. The per-share withholding price of $150.06 documents the valuation used for tax settlement. For investors, this is compliance and compensation administration activity; no new open-market trading or change in voting control is reported.

TL;DR Insider tax-withholding disclosure shows proper reporting and direct ownership of 30,811 shares after RSU settlement.

The Form 4 indicates timely and specific disclosure by an officer (CLO & Secretary), demonstrating adherence to Section 16 reporting obligations. The explicit explanation that shares were withheld to cover tax liabilities clarifies the nature of the transaction and mitigates potential concerns about opportunistic insider selling. This is a routine governance/compliance event without material governance implications.

Andrew Reardon, Chief Legal Officer e Segretario di Ligand Pharmaceuticals (LGND), ha comunicato che 1,325 azioni ordinarie sono state trattenute dall'emittente per soddisfare l'obbligo fiscale derivante dal regolamento delle unità azionarie vincolate (RSU). La ritenuta è stata effettuata usando un prezzo di $150.06 per azione.

Dopo la ritenuta, Reardon possiede beneficiariamente 30,811 azioni, riportate come proprietà diretta. Il deposito riporta il codice transazione F e la spiegazione del modulo dichiara esplicitamente che le azioni trattenute hanno pagato l'obbligo fiscale relativo al regolamento delle RSU. Questa comunicazione riflette una trattenuta di routine legata alla retribuzione e non una vendita o un acquisto sul mercato aperto.

Andrew Reardon, director legal y secretario de Ligand Pharmaceuticals (LGND), informó que el emisor retuvo 1,325 acciones ordinarias para satisfacer la obligación fiscal derivada del liquidación de unidades de acciones restringidas (RSU). La retención se realizó utilizando un precio de $150.06 por acción.

Tras la retención, Reardon posee beneficiariamente 30,811 acciones, reportadas como propiedad directa. La presentación indica el código de transacción F y la explicación del formulario declara explícitamente que las acciones retenidas pagaron la obligación fiscal de la liquidación de las RSU. Esta divulgación refleja una retención rutinaria relacionada con la compensación y no una venta o compra en el mercado abierto.

Andrew Reardonì€ Ligand Pharmaceuticals(LGND)ì� 최고법무책임ìž� ê²� 서기ì´ë©°, 발행ì¸ì´ 제한주ì‹ë‹¨ìœ„(RSU) ê²°ì œë¡� ë°œìƒí•� 세금 ë‚©ë¶€ë¥� 위해 1,325ì£� 보통ì£�ë¥� ì›ì²œì§•수했다ê³� 보고했습니다. ì›ì²œì§•수ëŠ� 주당 $150.06ì� ê°€ê²©ì„ ì‚¬ìš©í•˜ì—¬ ì´ë£¨ì–´ì¡ŒìŠµë‹ˆë‹�.

ì›ì²œì§•수 í›� ReardonëŠ� ì§ì ‘ 소유ë¡� ë³´ê³ ë� 30,811ì£�ë¥� 사실ìƒ� 보유하고 있습니다. 신고서ì—ëŠ� 거래 코드 Fê°€ 기재ë˜ì–´ 있으ë©�, ì–‘ì‹ì� ì„¤ëª…ì€ ì›ì²œì§•수ë� 주ì‹ì� RSU ê²°ì œì—� 대í•� 세금 ì˜ë¬´ë¥� 납부했다ê³� 명확íž� ë°ížˆê³� 있습니다. ì� 공시ëŠ� 공개 시장ì—서ì� 매매가 아니ë� ë³´ìƒ ê´€ë ¨ì˜ ì¼ìƒì ì¸ ì›ì²œì§•수ë¥� ë°˜ì˜í•©ë‹ˆë‹�.

Andrew Reardon, directeur juridique et secrétaire de Ligand Pharmaceuticals (LGND), a déclaré que l'émetteur avait retenu 1,325 actions ordinaires pour satisfaire l'obligation fiscale résultant du règlement d'unités d'actions restreintes (RSU). La retenue a été effectuée en utilisant un prix de $150.06 par action.

Après la retenue, Reardon détient bénéficiairement 30,811 actions, déclarées comme propriété directe. Le dépôt indique le code de transaction F et l'explication du formulaire précise explicitement que les actions retenues ont réglé l'obligation fiscale liée au règlement des RSU. Cette divulgation reflète une retenue courante liée à la rémunération et non une vente ou un achat sur le marché ouvert.

Andrew Reardon, Chief Legal Officer und Sekretär von Ligand Pharmaceuticals (LGND), meldete, dass vom Emittenten 1,325 Stammaktien einbehalten wurden, um die Steuerverpflichtung aus der Abwicklung von Restricted Stock Units (RSU) zu erfüllen. Die Einbehaltung erfolgte zu einem Preis von $150.06 je Aktie.

Nach der Einbehaltung besitzt Reardon wirtschaftlich 30,811 Aktien, angegeben als Direktbesitz. Die Meldung nennt den Transaktionscode F und die Erläuterung des Formulars führt ausdrücklich an, dass die einbehaltenen Aktien die Steuerverpflichtung bei der RSU-Abrechnung beglichen haben. Diese Offenlegung stellt eine routinemäßige, vergütungsbezogene Einbehaltung dar und keinen Kauf oder Verkauf am offenen Markt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Reardon Andrew

(Last) (First) (Middle)
555 HERITAGE DRIVE
SUITE 200

(Street)
JUPITER FL 33458

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
LIGAND PHARMACEUTICALS INC [ LGND ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CLO & Secretary
3. Date of Earliest Transaction (Month/Day/Year)
08/10/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/10/2025 F 1,325(1) D $150.06 30,811 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units.
/s/ Andrew Reardon 08/12/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Andrew Reardon report on Form 4 for LGND?

1,325 shares were withheld by the issuer to satisfy tax liability from settlement of restricted stock units; withholding price was $150.06 per share.

What is Andrew Reardon's role at Ligand Pharmaceuticals (LGND)?

Chief Legal Officer & Secretary; reported on the Form 4 as an officer with the title CLO & Secretary.

How many shares does Reardon beneficially own after the reported transaction?

30,811 shares of common stock, reported as direct beneficial ownership following the withholding.

What does the Form 4 explanation say about the withheld shares?

The form states the shares represent amounts withheld by the issuer to pay the tax liability arising from the settlement of restricted stock units.

Was this an open-market sale or purchase?

No. The filing reports issuer withholding of shares to cover taxes on RSU settlement, not an open-market transaction.
Ligand Pharma

NASDAQ:LGND

LGND Rankings

LGND Latest News

LGND Latest SEC Filings

LGND Stock Data

2.88B
18.83M
2.35%
99.7%
6.4%
Biotechnology
Pharmaceutical Preparations
United States
SAN DIEGO